Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI
| Autor(a) principal: | |
|---|---|
| Data de Publicação: | 2020 |
| Outros Autores: | , , , , , , , , , , , , , , , , , , |
| Tipo de documento: | Artigo |
| Idioma: | eng |
| Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| Texto Completo: | http://hdl.handle.net/10451/46744 |
Resumo: | © Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| id |
RCAP_ce65c272aa6472b9f463e5674f4689f2 |
|---|---|
| oai_identifier_str |
oai:repositorio.ul.pt:10451/46744 |
| network_acronym_str |
RCAP |
| network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository_id_str |
7160 |
| spelling |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAIDMARDs (biologic)Disease activitySpondyloarthritis© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.Objectives: To compare definitions of high disease activity of the Ankylosing Spondylitis Disease Activity Score (ASDAS) and Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) in selecting patients for treatment with biologic disease-modifying antirheumatic drugs (bDMARDs). Methods: Patients from Rheumatic Diseases Portuguese Register (Reuma.pt) with a clinical diagnosis of axial spondyloarthritis (axSpA) were included. Four subgroups (cross-tabulation between ASDAS (≥2.1) and BASDAI (≥4) definitions of high disease activity) were compared regarding baseline characteristics and response to bDMARDs at 3 and 6 months estimated in multivariable regression models. Results: Of the 594 patients included, the majority (82%) had both BASDAI≥4 and ASDAS ≥2.1. The frequency of ASDAS ≥2.1, if BASDAI<4 was much larger than the opposite (ie, ASDAS <2.1, if BASDAI≥4): 62% vs 0.8%. Compared to patients fulfilling both definitions, those with ASDAS ≥2.1 only were more likely to be male (77% vs 51%), human leucocyte antigen B27 positive (79% vs 65%) and have a higher C reactive protein (2.9 (SD 3.5) vs 2.1 (2.9)). Among bDMARD-treated patients (n=359), responses across subgroups were globally overlapping, except for the most ‘stringent’ outcomes. Patients captured only by ASDAS responded better compared to patients fulfilling both definitions (eg, ASDAS inactive disease at 3 months: 61% vs 25% and at 6 months: 42% vs 25%). Conclusion: The ASDAS definition of high disease activity is more inclusive than the BASDAI definition in selecting patients with axSpA for bDMARD treatment. The additionally ‘captured’ patients respond better and have higher likelihood of predictors thereof. These results support using ASDAS≥2.1 as a criterion for treatment decisions.This work was supported by a Research Grant from the Investigator-Initiated Studies program of Merck Sharp & Dohme (Grant No. 56078). The sponsor did not interfere with the study question, analysis or interpretation of results. AS is supported by a doctoral grant from Fundação para a Ciência e Tecnologia (Foundation for Science and Technology) (SFRH/BD/108246/2015).BMJ Publishing Group, Ltd.Repositório da Universidade de LisboaMarona, JoseSepriano, AlexandreRodrigues-Manica, SantiagoPimentel-Santos, FernandoMourão, Ana FilipaGouveia, NéliaBranco, Jaime CunhaSantos, HelenaVieira de Sousa, Elsa CristinaVinagre, FilipeTavares-Costa, JoãoRovisco, JoãoBernardes, MiguelMadeira, NathalieMachado, Ana RitaRoque, RaquelSilva, Joana LeiteMarques, Mary LucyFerreira, Raquel MiriamRamiro, Sofia2021-03-09T14:20:02Z20202020-01-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttp://hdl.handle.net/10451/46744engRMD Open. 2020 Jan;6(1):e00114510.1136/rmdopen-2019-0011452056-5933info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2023-11-08T16:49:12Zoai:repositorio.ul.pt:10451/46744Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T21:58:50.165024Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
| dc.title.none.fl_str_mv |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| title |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| spellingShingle |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI Marona, Jose DMARDs (biologic) Disease activity Spondyloarthritis |
| title_short |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| title_full |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| title_fullStr |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| title_full_unstemmed |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| title_sort |
Eligibility criteria for biologic disease-modifying antirheumatic drugs in axial spondyloarthritis : going beyond BASDAI |
| author |
Marona, Jose |
| author_facet |
Marona, Jose Sepriano, Alexandre Rodrigues-Manica, Santiago Pimentel-Santos, Fernando Mourão, Ana Filipa Gouveia, Nélia Branco, Jaime Cunha Santos, Helena Vieira de Sousa, Elsa Cristina Vinagre, Filipe Tavares-Costa, João Rovisco, João Bernardes, Miguel Madeira, Nathalie Machado, Ana Rita Roque, Raquel Silva, Joana Leite Marques, Mary Lucy Ferreira, Raquel Miriam Ramiro, Sofia |
| author_role |
author |
| author2 |
Sepriano, Alexandre Rodrigues-Manica, Santiago Pimentel-Santos, Fernando Mourão, Ana Filipa Gouveia, Nélia Branco, Jaime Cunha Santos, Helena Vieira de Sousa, Elsa Cristina Vinagre, Filipe Tavares-Costa, João Rovisco, João Bernardes, Miguel Madeira, Nathalie Machado, Ana Rita Roque, Raquel Silva, Joana Leite Marques, Mary Lucy Ferreira, Raquel Miriam Ramiro, Sofia |
| author2_role |
author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Repositório da Universidade de Lisboa |
| dc.contributor.author.fl_str_mv |
Marona, Jose Sepriano, Alexandre Rodrigues-Manica, Santiago Pimentel-Santos, Fernando Mourão, Ana Filipa Gouveia, Nélia Branco, Jaime Cunha Santos, Helena Vieira de Sousa, Elsa Cristina Vinagre, Filipe Tavares-Costa, João Rovisco, João Bernardes, Miguel Madeira, Nathalie Machado, Ana Rita Roque, Raquel Silva, Joana Leite Marques, Mary Lucy Ferreira, Raquel Miriam Ramiro, Sofia |
| dc.subject.por.fl_str_mv |
DMARDs (biologic) Disease activity Spondyloarthritis |
| topic |
DMARDs (biologic) Disease activity Spondyloarthritis |
| description |
© Author(s) (or their employer(s)) 2020. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. |
| publishDate |
2020 |
| dc.date.none.fl_str_mv |
2020 2020-01-01T00:00:00Z 2021-03-09T14:20:02Z |
| dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
| dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10451/46744 |
| url |
http://hdl.handle.net/10451/46744 |
| dc.language.iso.fl_str_mv |
eng |
| language |
eng |
| dc.relation.none.fl_str_mv |
RMD Open. 2020 Jan;6(1):e001145 10.1136/rmdopen-2019-001145 2056-5933 |
| dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
BMJ Publishing Group, Ltd. |
| publisher.none.fl_str_mv |
BMJ Publishing Group, Ltd. |
| dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
| instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| instacron_str |
RCAAP |
| institution |
RCAAP |
| reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
| repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
| repository.mail.fl_str_mv |
|
| _version_ |
1799134534226149376 |